The Little Canada, Minn.-based medical device company was founded in 1976 by medtech legend Dr. Manny Villafaña to make surgical, bi-leaflet replacement valves. Today the company said more than 3 million patients have been implanted with its valves, including the Trifecta GT, which launched in Europe last month after winning CE Mark approval there in February.
The valve’s titanium stent is covered with tissue to improve tissue-to-tissue contact during the leaflets’ motion. St. Jude said the Trifecta GT also features its Linx anti-calcification treatment.
“Founded as a pioneering manufacturer of implantable bi-leaflet mechanical heart valves, St. Jude Medical has dedicated significant resources to develop best-in-class heart valve replacement options while refining our devices based on physician feedback and clinical outcomes,” chief medical officer Dr. Mark Carlson said in prepared remarks. “The Trifecta GT tissue valve is a true testament of our commitment to the cardiac surgery community and the patients they treat by improving the ability to implant the valve when encountering challenging anatomies and during minimally invasive surgical approaches.”
“The new tissue valve offers enhancements that will only make the implantation process smoother, providing a solution to patients with even the most challenging of cases,” added Dr. Trey Pluscht of Alabama’s Cardio-Thoracic & Vascular Surgical Assoc. “I welcome the opportunity to offer patients the life-changing benefits we’ve come to expect from this family of valves.”
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.